Novo Holdings A/S
Novo Holdings A/S's purchase track record
How the stock did after each of Novo Holdings A/S's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/1/2026 | AVLN | $10.00M | -3.5% | pending | — |
| 10/28/2025 | MPLT | $16.20M | +14.3% | +81.0% | +3.6% |
| 2/9/2024 | MGX | $13.03M | -36.5% | -72.1% | +6.3% |
| 2/16/2023 | SPRB | $7.00M | -10.0% | -7.2% | +6.8% |
| 9/14/2022 | EWTX | $5.00M | -22.7% | -26.9% | -1.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
AVLN releases Phase 1 data for AP02 inhaled therapy. Avalyn Pharma released Phase 1 results for its inhaled antifibrotic candidate AP02. The trials in healthy volunteers and patients with idiopathic pulmonary fibrosis showed lung‑targeted delivery and an encouraging safety profile. The publication follows recent discussion of the company's valuation and adds clinical evidence supporting the inhaled approach.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MapLight Therapeutics Shares Fall 34.8% in Four Weeks. MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Citizens Maintains $144 Target for Spruce Biosciences. Citizens Capital Markets has reaffirmed a market‑outperform rating for Spruce Biosciences and kept its $144 price target. The target sits well above the current trading level and within the company’s 52‑week range, suggesting upside potential. Analysts average a target of $148, with a wide range from $104 to $230. The stock’s RSI of 37.6 and a support level at $48.43 indicate it is not in overbought territory.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Metagenomi Therapeutics to Speak at Chardan Healthcare Conference. Metagenomi Therapeutics announced it will participate in the Chardan 10th Annual Healthcare Conference. This event provides a platform for the company to share updates with industry professionals and investors. The stock is currently trading near its 52-week low, making this upcoming presentation a notable point of interest for observers tracking the company's developments.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Disc Medicine faces valuation scrutiny and whale activity. Recent commentary questions whether Disc Medicine's stock price fully reflects its market position relative to competitors. Additionally, the stock appeared on a list of healthcare names showing significant large-scale trading activity. The stock is currently trading near its 52-week low, which provides context for these recent market observations.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Edgewise Therapeutics Doses First Patient in Phase 2 Trial. Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.
Transaction History
| COAG | ▼ Sell | Other | 4,180,550 | — | 5/4/2026 | View on chart |
| AVLN | ▼ Sell | Other | 3,327,734 | — | 5/1/2026 | View on chart |
| AVLN | ▲ Buy | Open Market | 555,555 | $10.0M | 5/1/2026 | View on chart |
| MPLT | ▼ Sell | Other | 2,733,681 | — | 10/28/2025 | View on chart |
| MPLT | ▲ Buy | Open Market | 952,941 | $16.2M | 10/28/2025 | View on chart |
| SPRB | ▼ Sell | Open Market | 465,021 | $351K | 3/21/2024 | View on chart |
| SPRB | ▼ Sell | Open Market | 359,979 | $264K | 3/20/2024 | View on chart |
| SPRB | ▼ Sell | Open Market | 593,000 | $448K | 3/19/2024 | View on chart |
| SPRB | ▼ Sell | Open Market | 842,020 | $647K | 3/18/2024 | View on chart |
| SPRB | ▼ Sell | Open Market | 1,912,316 | $1.7M | 3/14/2024 | View on chart |
| MGX | ▼ Sell | Other | 839,175 | — | 2/13/2024 | View on chart |
| MGX | ▲ Buy | Open Market | 800,000 | $12.0M | 2/13/2024 | View on chart |
| MGX | ▲ Buy | Open Market | 100,000 | $1.0M | 2/9/2024 | View on chart |
| IRON | ▼ Sell | Open Market | 1,250,000 | $57.6M | 6/28/2023 | View on chart |
| OKUR | ▼ Sell | Open Market | 100,000 | $710K | 6/23/2023 | View on chart |
| SPRB | ▲ Buy | Open Market | 2,208,000 | $7.0M | 2/16/2023 | View on chart |
| EWTX | ▲ Buy | Open Market | 484,496 | $5.0M | 9/14/2022 | View on chart |
| BOLT | ▼ Sell | Open Market | 800,000 | $1.6M | 7/13/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Rodman & Renshaw initiates coverage on Hemab Therapeutics
Rodman & Renshaw has begun tracking Hemab Therapeutics, assigning a Buy rating and a price target of $56. This is a new entry in the analyst coverage for the stock, which currently trades near its 52-week low. The firm's target is slightly below the current average analyst estimate of $61.20.
Rodman & Renshaw initiates coverage on Hemab Therapeutics. Rodman & Renshaw has begun tracking Hemab Therapeutics, assigning a Buy rating and a price target of $56. This is a new entry in the analyst coverage for the stock, which currently trades near its 52-week low. The firm's target is slightly below the current average analyst estimate of $61.20.